Videos

The panel closes their discussion with a look at an ongoing clinical trial in transplant-ineligible NDMM.

Dr Sandy Wong reviews data from a patient subgroup analysis of the MAIA trial in transplant-ineligible NDMM.

Myeloma experts share their thoughts on the future of multiple myeloma treatment.

Experts on multiple myeloma compare their treatment sequencing strategies.

Nazy Zomorodian, NP, spoke with CancerNetwork® about the unique dosing schedule of enfortumab vedotin plus pembrolizumab following its accelerated approval by the FDA in advanced/metastatic urothelial cancer.

An esteemed panel of experts overviews new approaches being explored for treating graft-vs-host disease.

A detailed discussion on first-line treatment options for chronic GVHD and options for patients with steroid-refractory chronic GVHD.

An expert from Dana-Farber Cancer Institute indicates that urologists should refer patients with prostate cancer who present with multiple high-risk factors at surgery to a radiation and medical oncologist.

Fifteen-year results of the ProtecT prostate cancer trial may support the findings of the study’s 10-year follow-up data, according to an expert from Dana-Farber Cancer Institute.

Drs Chao and Grunwald review available treatment options as informed by NCCN guidelines for patients with steroid-refractory acute Graft-Versus-Host Disease.

Nelson J. Chao, MD, MBA, and Michael Grunwald, MD introduce acute Graft-Versus-Host Disease (GvHD), sharing how it is diagnosed, how it differs from chronic GvHD, and common signs and symptoms.

Shared insight on the treatment armamentarium for metastatic renal cell carcinoma and how these options should be communicated with patients.

Increasing age, higher Gleason scores, and higher pathologic stages are predictors of mortality in patients with prostate cancer, according to an expert from Dana-Farber Cancer Institute.

Centering discussion on a clinical scenario of metastatic renal cell carcinoma, expert panelists reflect on optimal diagnosis and stratification methods in this setting.

Healthcare professionals reflect on recent evolutions in the renal cell carcinoma treatment landscape.

Panelists share their perspective on establishing a support network for patients undergoing treatment for renal cell carcinoma.

Clinical trials highlight benefits, including radiographic progression-free survival following treatment with radioligand 177Lu-PSMA-617 in pretreated patients with metastatic castration-resistant prostate cancer.

Shaji Kumar, MD, presents data from an updated analysis of the MAIA trial investigating daratumumab/lenalidomide/dexamethasone for transplant-ineligible NDMM.

The panel compares data between the three presented quadruplet combination regimens for NDMM, and which they would consider for older, frail patients.

Early data from ongoing clinical trials suggest the potential safety and efficacy of novel radium-223 combinations as treatment for metastatic castration-resistant prostate cancer.

Noa Biran, MD, offers insights on ongoing research with bispecific antibodies in multiple myeloma.

A comprehensive discussion on bispecific antibodies and T-cell engagers in the treatment of multiple myeloma.

Experts on graft-vs-host disease discuss patient monitoring and education, and a patient details his experience with GVHD.

A panel of GVHD experts give a comprehensive overview of the presentations of acute and chronic graft-vs-host disease.

An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.

The use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.

Minimally invasive surgery for interval debulking resulted in a lower mortality at the 30- and 90-day time points compared with laparotomy in advanced ovarian cancer.

Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.

An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.

Laura Sanza, PhD, MPAS, PA-C, leads a discussion on communicating adverse events with patients and mitigating potential toxicities.